RedHill Biopharma Ltd.
RDHL · XNASCIK 1553846fmd_1MN6NDBH6S3QTA3JWN0BEYTA07Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 20 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 4 | 8 | 6 | 64 | 86 | 62 | 7 | 8 |
| Cost of revenue | – | – | 2 | 3 | 2 | 37 | 49 | 33 | 3 | 3 |
| Gross profit | 0 | 0 | 2 | 6 | 4 | 27 | 36 | 28 | 3 | 5 |
| Research and development | 18 | 25 | 33 | 25 | 17 | 16 | 29 | 7 | 4 | 2 |
| Selling, general and administrative | 3 | 4 | 8 | 8 | 11 | 25 | 32 | 29 | 16 | 10 |
| Operating income | (22) | (31) | (52) | (39) | (43) | (64) | (81) | (43) | 13 | (15) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 13 | 17 | 42 | 10 | 2 |
| Net income | (21) | (29) | (46) | (39) | (42) | (76) | (98) | (72) | 24 | (8) |
| Net income to common shareholders | (21) | (29) | (46) | (39) | (42) | (76) | (98) | (72) | 24 | (8) |